FHL’s Clinical Pipeline
FHL has developed a portfolio of seven candidate and combination drugs, with the potential to develop monoclonal antibody (mAb) assets in the long-term. Our drug candidates show potential to slow or reverse disease progression with minimal side effects and improve the quality of life of patients and their families. During preclinical studies, our pipeline candidates have demonstrated an increase in neuronal protection, clearing of pathogenic molecules via lysosomal biogenesis, and attenuation of inflammation in the brain.
With the adoption of precision-medicine and a patient-focused model,
FHL seeks to establish robust patient recruitment criteria to select and
enrol the right target groups based on objective measures related to
disease progression.
Status Overview
- DRUG CANDIDATE
- REGULATORY PATHWAY
- Pre-Clinical
- Phase 1
- Phase 2
- SMALL
MOLECULE -
FHL-101
FHL-201
FHL-301
FHL-601
FHL-901 (Combo)
-
New Chemical Entity
New Chemical Entity
Refocused Drug
Refocused Drug
New Chemical Entity
-
- PEPTIDES
-
FHL-401
FHL-501
-
New Chemical Entity
New Chemical Entity
-
- ANTIBODIES -
OPTIONED FOR
LONG-TERM
DEVELOPMENT -
FHL-701
FHL-801
-
New Chemical Entity
New Chemical Entity
-
DRUG CANDIDATE |
Primary Indications |
regulatory pathway |
ANIMAL POCs | additional indications | ||||
---|---|---|---|---|---|---|---|---|
Dopamine increase |
inflammatory molecules decrease |
Neuronal Protection |
Functional Improvement |
|||||
SMALL Molecule |
FHL-101 | PD | NCE | - | ||||
FHL-201 | AD / PD | NCE | Multiple sclerosis | |||||
FHL-301 | AD / PD | Refocused | Multiple sclerosis | |||||
FHL-601 | PD | Refocused | - | |||||
FHL-901 (Combo) * | Huntington’s | NCE | - | - | - | - | Alzheimer’s disease, Parkinson’s disease |
|
PEPTIDES | FHL-401 | AD / PD | NCE | Multiple system atrophy. Lewy body dementia |
||||
FHL-501 | AD / PD | NCE | Stroke, Lewy Body Dementia |
* Data under review